Meliglix

Sitagliptin, the active ingredient in Meliglix, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise, and in combination with other antidiabetic agents as appropriate.

GNH USA supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation for export to ensure reliable global distribution.

Sitagliptin, marketed as Meliglix, acts on the incretin pathway to improve blood glucose regulation in type 2 diabetes. - Type 2 diabetes mellitus: improves glycaemic control as monotherapy or in combination with other antidiabetic agents. - Adjunct to diet and exercise: enhances the effect of lifestyle modifications on glucose levels. - Combination with metformin: provides additional HbA1c reduction when used together.

Sitagliptin may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Nasopharyngitis: inflammation of the nasal passages and throat. - Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be disabling. - Stevens‑Johnson syndrome: rare but life‑threatening skin eruption.

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: assess kidney function and adjust dose or avoid use in severe cases. - Hepatic impairment: use with caution and monitor liver enzymes. - History of pancreatitis: avoid sitagliptin due to risk of recurrence. - Elderly patients: monitor for hypoglycaemia, especially when combined with insulin or sulfonylureas. - Concomitant medications: review for potential drug interactions before initiating therapy. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Sitagliptin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Insulin or sulfonylureas: combined use may cause significant hypoglycaemia; avoid unless closely supervised. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase sitagliptin plasma levels and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism and may lower sitagliptin exposure, reducing effectiveness. - ACE inhibitors or ARBs: monitor renal function and potassium levels when used together. - Diuretics: observe for changes in blood glucose and electrolytes.